Rituximab combined with liposomal doxorubicin (R-Dox) in HIV-infected patients with severe Kaposi sarcoma-associated herpes virus (KSHV) associated multicentric Castleman disease (MCD)

Ítems similars

• Rituximab combined with liposomal doxorubicin (R-Dox) in HIV-infected patients with severe Kaposi sarcoma-associated herpes virus (KSHV) associated multicentric Castleman disease (MCD)
  per: Tosato Giovanna, et al.
  Publicat: (2010-10-01)
• Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease
  per: Uldrick, Thomas S., et al.
  Publicat: (2014)
• Interim results of a clinical trial using oncolytic virotherapy in Kaposi's sarcoma-associated herpesvirus (KSHV) associated-Multicentric Castleman's Disease (MCD)
  per: Yarchoan, R, et al.
  Publicat: (2009)
• KSHV activation, human and viral IL-6 production, and other cytokine dysregulation: Association with the symptomatology of KSHV-associated multicentric Castleman’s disease
  per: Polizzotto, Mark N, et al.
  Publicat: (2010)
• Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV–MCD) and the KSHV Inflammatory Cytokine Syndrome
  per: Mark N. Polizzotto, et al.
  Publicat: (2012-03-01)